BIOVANCE is an amniotic membrane allograft derived from a natural source — the placenta of a healthy, full-term human pregnancy. The progenerative power of the amniotic membrane supports the body’s natural ability to restore tissue to a pre-wound state.1-6

The natural function of the amniotic membrane brings protection and support to the wound it covers.1-6

  • Reduces inflammation4,6
  • Supports tissue growth6
  • Provides a biological barrier to infection6
  • Minimizes pain upon application3,4
  • Maintains a moist wound environment4


BIOVANCE is indicated for a broad range of wound types, including, but not limited to:

  • Acute
  • Chronic
  • Mohs surgery
  • Burns
  • Trauma
  • Exposed tendon, muscle, bone
  • Complex
  • Surgical
  • Venous leg ulcers
  • Diabetic ulcers
  • Pressure ulcers
  • Arterial ulcers


BIOVANCE is minimally processed to maximize natural benefits and safety. The immunologically inert tissue:

  • Contains no antigens,6 which further minimizes the risk of inflammatory response
  • Chorion layer is removed to further support the natural healing process
    • Eliminates cellular debris
    • Avoids potential addition of MMPs to the wound7
    • Prevents need for specific orientation for placement


Ease of application and wound visualization:

  • Translucent grid pattern is evident on the wound until hydration to allow view of the wound’s progress
  • BIOVANCE is flexible to conform to irregular surfaces
  • BIOVANCE can be applied with either side facing the wound, and can be sutured, taped, stapled, or glued, as determined by the clinician
  • BIOVANCE should be applied to a clean wound and covered with an appropriate secondary, non-adherent dressing


Off-the-shelf availability for a broad range of wounds.

  • 5-year shelf life eliminates need for pre-ordering
  • Room temperature storage (no refrigeration necessary)


Availability in multiple sizes for application flexibility:



  1. Bhatia M, Pereira M, Rana H, et al. Mechanism of cell interaction and response on decellularized human amniotic membrane: implications in wound healing. Wounds. 2007;19(8):207-217.
  2. Faulk WP, Matthews R, Stevens PJ, et al. Human amnion as an adjunct in wound healing. Lancet. 1980;1(8179):1156-1158.
  3. Fetterolf DE, Synder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds. 2012;24(10):299-307.
  4. Ganatra MA. Amniotic membrane in surgery. J Pak Med A. 2003;v53(1):29-32.
  5. Portmann-Lanz CB, Ochsenbein-Kölble N, Marquardt K, et al. Manufacture of a cell-free amnion matrix scaffold that supports amnion cell outgrowth in vitro. Placenta. 2007;28(1):6-13. Epub2006.
  6. Niknejad H, Peirovl H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. European Cells and Materials. 2008;15:88-99.
  7. Arechavaleta-Velasco F, Marciano D, Díaz-Cueto L, Parry S. Matrix metalloproteinase-8 is expressed in human chorion during labor. Am J Obstet Gynecol. 2004;190:843-850.